Research programme: urokinase plasminogen activator inhibitors - Dendreon

Drug Profile

Research programme: urokinase plasminogen activator inhibitors - Dendreon

Alternative Names: U-PA antagonists research programme - Dendreon; Urokinase plasminogen activator inhibitors research programme - Dendreon

Latest Information Update: 16 May 2007

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
  • 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC
  • 12 Sep 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top